KLG Stock +78.58% In 3 Months Since We Picked KLG Stock +78.58% In 3 Months Since We Picked Unlock All Top Buy Picks

Latest Data & Signals Issued

Signal Type Signal Value Data
Score -0.439 1 day ( 0 % )
Last Price $40.10 1.52 %
High/ Low $38.85 - $40.82 3.17%
Chg 7 Days -0.521 % $40.31 $40.10
Chg 30 Days -6.00 % $42.66 $40.10
Chg 12 mos 1.47 % $39.52 $40.10
Trend - 3 mos -16.41 % Width: 11.60 %
Trend - 12 mos 13.87 % Width: 63.41 %
Pred. range - 3 mos $32.90 - $36.72 -17.95 % - -8.43 %
Pred. range - 12 mos $35.77 - $58.46 -10.79 % - 45.78 %
Short MA avg 3 mos Buy Apr 22, 2024 - 4 days
Long MA avg 3 mos Sell Feb 29, 2024 - 40 days
Short/Long MA avg 3 mos Sell Mar 06, 2024 - 36 days
Short MA avg 12 mos Sell Feb 27, 2024 - 42 days
Long MA avg 12 mos Buy Apr 08, 2024 - 14 days
Short/Long MA avg 12 mos Sell Apr 09, 2024 - 13 days
Pivot Short Buy Apr 24, 2024 - 2 days
Bollinger Buy Apr 24, 2024 - 2 days
MACD Sell No Dates Stored For This Signal

Signals Effectiveness

Backtesting is not only a way to check stock signal accuracy, but also a tool to continually improvement. Data can be used for self adjustment as each stock has an individual behavior.

Accuracy and return is not the same. A stock signal may provide low statistical accuracy, but the signals may prove high return in average.

Sharp market dips or fundamental changes (earning reports, news updates etc), may force a short term reaction and disturb the signals (Signals may jump quickly from buy to sell, just to return to buy).

Stock Score

Buy Signals
Sell Signals

Bollinger Bands

Buy Signals
Sell Signals

MACD

Buy Signals
Sell Signals

Moving Average (7d)

Buy Signals
Sell Signals
Click to get the best stock tips daily for free!

About Xenon Pharmaceuticals Inc.

Xenon Pharmaceuticals. Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, A Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epilepsy encephalopathy; and XEN1101, A Kv7 potassium channel opener, which is in Phase II clinical trial for the treatment o... XENE Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT